Syndax Pharmaceuticals, Inc. (SNDX) vs Taysha Gene Therapies, Inc. (TSHA)

Syndax Pharmaceuticals, Inc. and Taysha Gene Therapies, Inc. are both Biotechnology companies. Syndax Pharmaceuticals, Inc. and Taysha Gene Therapies, Inc. are of similar size ($1.6B and $1.6B). Syndax Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 222.3% against 19.0%. Taysha Gene Therapies, Inc. has the higher net margin (0.00% vs −87.6%) and the higher return on invested capital (0.00% vs −247.9%). Across the 17 metrics below, Taysha Gene Therapies, Inc. leads on 11 and Syndax Pharmaceuticals, Inc. on 6.

Valuation

Metric SNDX TSHA Biotechnology median
P/E n/m n/m 7.88
P/S 6.43 146.12 11.47
P/B 107.27 4.45 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 6.65 111.68 10.73
Earnings yield (13.79%) (8.99%) (28.84%)
Free cash flow yield (13.64%) (8.07%) (23.03%)

Profitability

Metric SNDX TSHA Biotechnology median
Gross margin 95.78% 100.00% 65.16%
Operating margin (77.05%) 0.00% 0.00%
Net margin (87.60%) 0.00% 0.00%
Free cash flow margin (87.64%) 0.00% 0.00%
Return on equity (255.93%) (47.05%) (57.72%)
Return on assets (33.97%) (37.23%) (49.22%)
Return on invested capital (247.93%) 0.00% 0.00%

Growth

Metric SNDX TSHA Biotechnology median
Revenue growth (TTM) 222.34% 18.96% 5.64%
EPS growth (last fiscal year) 11.56% 5.56% —
Revenue growth, 5-year CAGR 157.68% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric SNDX TSHA Biotechnology median
Debt to equity 38.95 0.13 0.00
Current ratio 6.77 17.76 4.73
Net debt to EBITDA 0.25 2.47 0.96

Dividend

Metric SNDX TSHA Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric SNDX TSHA Biotechnology median
Market cap 1.60b 1.56b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack